endopredict tests (Sividon Diagnostics GmbH)
90
Structured Review
Sividon Diagnostics GmbH
endopredict tests

Endopredict Tests, supplied by Sividon Diagnostics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict/endopredict+test/pmc04180906-115-0-2
Average 90 stars, based on 1 article reviews

Endopredict Tests, supplied by Sividon Diagnostics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/endopredict/endopredict+test/pmc04180906-115-0-2
Average 90 stars, based on 1 article reviews
endopredict tests - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer"
Article Title: Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer
Journal: Virchows Archiv
doi: 10.1007/s00428-014-1652-0
Figure Legend Snippet: EndoPredict test results achieved after different storage times and temperatures before fixation. The solid line represents the reference score which was derived from the mean EP score of the tissue sections that have been stored for 10 min at 20 °C before fixation. Dotted lines represent the reference score ±3× its standard deviation as determined by precision study . Measurements were performed in duplicate ( n = 2). Mean values are presented, with standard errors of the means indicated by bars
Techniques Used: Derivative Assay, Standard Deviation
Figure Legend Snippet: EndoPredict test results achieved after different fixation times. The solid line represents the reference score which was derived from the mean EP score of the tissue sections that have been fixed for 20 h in neutral buffered formalin. Dotted lines represent the reference score ±3× its standard deviation as determined by precision study . Measurements were performed in duplicate ( n = 2). Mean values are presented, with standard errors of the means indicated by bars
Techniques Used: Derivative Assay, Standard Deviation
Figure Legend Snippet: Correlation of the relative expression values of the EndoPredict genes of interest between whole sections and manually microdissected sections
Techniques Used: Expressing
Figure Legend Snippet: Correlation between the EP ( a ) and EPclin ( b ) scores of paired whole and tumor-enriched, manually microdissected tissue sections from ER+/HER2− breast cancer patients ( n = 39). Pearson correlation coefficient of EP scores was 0.97 with a concordance of EndoPredict risk classification of 87 %. Pearson correlation coefficient of EPclin scores was 0.98 with a concordance of EndoPredict risk classification of 95 %. Black filled circles represent tissue samples with TCC ≥30 %, open circles tissue sections with TCC <30 %
Techniques Used:
Figure Legend Snippet: Mean difference of relative expression values (delta Cq value [nonstored]-delta Cq value [stored]) of the EndoPredict genes of interest between nonstored and stored FFPE tissue sections
Techniques Used: Expressing
Figure Legend Snippet: Correlation of EP scores between stored and nonstored FFPE tissue sections. EP scores have been determined at the beginning of the study, after 12 months at +4 °C ( a ) or after 12 months at +20 °C ( b ), respectively. Pearson correlation coefficients were 0.99 and >0.99 with a concordance of EndoPredict risk classification of 100 %
Techniques Used:
Related Articles
Expressing:Article Title: Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers Article Snippet: .. The Prosigna test (previously known as PAM50; NanoString Technologies, Seattle, WA, USA) , measures the expression of 50 genes at the mRNA level, the other:Article Title: Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor Article Snippet: Karsten Weber holded shares in Sividon Diagnostics, holds patent property for the Article Title: Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial Article Snippet: Karsten Weber holds shares from Sividon Diagnostics and patent property for the Gene Expression:Article Title: Gene Expression Analyses in Early Breast Carcinoma — Quo Vadis? Article Snippet: .. Quantitative RT-PCR:Article Title: Gene Expression Analyses in Early Breast Carcinoma — Quo Vadis? Article Snippet: .. Reverse Transcription Polymerase Chain Reaction:Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Article Snippet: .. The Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons Article Snippet: .. Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons Article Snippet: .. The Formalin-fixed Paraffin-Embedded:Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Article Snippet: .. The Article Title: Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes . Article Snippet: .. The Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons Article Snippet: .. Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons Article Snippet: .. The Biomarker Discovery:Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Article Snippet: .. The Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons Article Snippet: .. Article Title: Molecular Genomic Testing for Breast Cancer: Utility for Surgeons Article Snippet: .. The Real-time Polymerase Chain Reaction:Article Title: Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes . Article Snippet: .. The |